David Kimball, PhD, has over 40 years’ experience in drug discovery, drug development and scientific innovation in pharma, biotech, and academia. During his career, including as Senior Vice President of Research for Rutgers University, David has played a leading role in the discovery and development of a dozen clinical compounds.

When Kimball retired from Rutgers  in 2021, he was responsible for the management of $750M in research expenditures, research grants, contracts, core facilities, technology commercialization and corporate engagement.  David also created the Rutgers Biomedical Research Innovation Cores (RUBRIC) group and was a Research Professor in the Ernest Mario School of Pharmacy.

David obtained his PhD in Organic Chemistry/Chemical Biology from the State University of New York at Stony Brook in 1982 and spent the first 19 years of his career at Bristol-Myers Squibb Pharmaceutical Research Institute, leading drug discovery and development efforts in cardiovascular medicine and oncology. In 2001, he moved to Lexicon Pharmaceuticals in Princeton, NJ as Vice President of Chemistry and directed discovery and development chemistry efforts for Lexicon’s entire clinical pipeline of small molecules. David also served as Senior Vice President of Nonclinical Research at Pharmacopeia, Inc., and Chief Scientific Officer of Hydra Biosciences, in Cambridge, MA prior to joining Rutgers in 2011.